Arran K Turnbull1, Laura M Arthur1, Lorna Renshaw1, Alexey A Larionov1, Charlene Kay1, Anita K Dunbier1, Jeremy S Thomas1, Mitch Dowsett1, Andrew H Sims2, J Michael Dixon1. 1. Arran K. Turnbull, Laura M. Arthur, Lorna Renshaw, Alexey A. Larionov, Charlene Kay, Jeremy S. Thomas, Andrew H. Sims, J. Michael Dixon, University of Edinburgh Cancer Research UK Centre, Edinburgh; Anita K. Dunbier, Mitch Dowsett, Institute of Cancer Research, London, United Kingdom; and Anita K. Dunbier, University of Otago, Dunedin, New Zealand. 2. Arran K. Turnbull, Laura M. Arthur, Lorna Renshaw, Alexey A. Larionov, Charlene Kay, Jeremy S. Thomas, Andrew H. Sims, J. Michael Dixon, University of Edinburgh Cancer Research UK Centre, Edinburgh; Anita K. Dunbier, Mitch Dowsett, Institute of Cancer Research, London, United Kingdom; and Anita K. Dunbier, University of Otago, Dunedin, New Zealand. andrew.sims@ed.ac.uk.
Abstract
PURPOSE: Aromatase inhibitors (AIs) have an established role in the treatment of breast cancer. Response rates are only 50% to 70% in the neoadjuvant setting and lower in advanced disease. Accurate biomarkers are urgently needed to predict response in these settings and to determine which individuals will benefit from adjuvant AI therapy. PATIENTS AND METHODS: Pretreatment and on-treatment (after 2 weeks and 3 months) biopsies were obtained from 89 postmenopausal women who had estrogen receptor-alpha positive breast cancer and were receiving neoadjuvant letrozole for transcript profiling. Dynamic clinical response was assessed with use of three-dimensional ultrasound measurements. RESULTS: The molecular response to letrozole was characterized and a four-gene classifier of clinical response was established (accuracy of 96%) on the basis of the level of two genes before treatment (one gene [IL6ST] was associated with immune signaling, and the other [NGFRAP1] was associated with apoptosis) and the level of two proliferation genes (ASPM, MCM4) after 2 weeks of therapy. The four-gene signature was found to be 91% accurate in a blinded, completely independent validation data set of patients treated with anastrozole. Matched 2-week on-treatment biopsies were associated with improved predictive power as compared with pretreatment biopsies alone. This signature also significantly predicted recurrence-free survival (P = .029) and breast cancer -specific survival (P = .009). We demonstrate that the test can also be performed with use of quantitative polymerase chain reaction or immunohistochemistry. CONCLUSION: A four-gene predictive model of clinical response to AIs by 2 weeks has been generated and validated. Deregulated immune and apoptotic responses before treatment and cell proliferation that is not reduced 2 weeks after initiation of treatment are functional characteristics of breast tumors that do not respond to AIs.
PURPOSE: Aromatase inhibitors (AIs) have an established role in the treatment of breast cancer. Response rates are only 50% to 70% in the neoadjuvant setting and lower in advanced disease. Accurate biomarkers are urgently needed to predict response in these settings and to determine which individuals will benefit from adjuvant AI therapy. PATIENTS AND METHODS: Pretreatment and on-treatment (after 2 weeks and 3 months) biopsies were obtained from 89 postmenopausal women who had estrogen receptor-alpha positive breast cancer and were receiving neoadjuvant letrozole for transcript profiling. Dynamic clinical response was assessed with use of three-dimensional ultrasound measurements. RESULTS: The molecular response to letrozole was characterized and a four-gene classifier of clinical response was established (accuracy of 96%) on the basis of the level of two genes before treatment (one gene [IL6ST] was associated with immune signaling, and the other [NGFRAP1] was associated with apoptosis) and the level of two proliferation genes (ASPM, MCM4) after 2 weeks of therapy. The four-gene signature was found to be 91% accurate in a blinded, completely independent validation data set of patients treated with anastrozole. Matched 2-week on-treatment biopsies were associated with improved predictive power as compared with pretreatment biopsies alone. This signature also significantly predicted recurrence-free survival (P = .029) and breast cancer -specific survival (P = .009). We demonstrate that the test can also be performed with use of quantitative polymerase chain reaction or immunohistochemistry. CONCLUSION: A four-gene predictive model of clinical response to AIs by 2 weeks has been generated and validated. Deregulated immune and apoptotic responses before treatment and cell proliferation that is not reduced 2 weeks after initiation of treatment are functional characteristics of breast tumors that do not respond to AIs.
Authors: Jeffrey West; Mark Robertson-Tessi; Kimberly Luddy; Derek S Park; Drew F K Williamson; Cathal Harmon; Hung T Khong; Joel Brown; Alexander R A Anderson Journal: JCO Clin Cancer Inform Date: 2019-02
Authors: Diana E Ramirez-Ardila; Kirsten Ruigrok-Ritstier; Jean C Helmijr; Maxime P Look; Steven van Laere; Luc Dirix; Els M J J Berns; Maurice P H M Jansen Journal: Mol Oncol Date: 2016-07-25 Impact factor: 6.603
Authors: Aleix Prat; Ana Lluch; Arran K Turnbull; Anita K Dunbier; Lourdes Calvo; Joan Albanell; Juan de la Haba-Rodríguez; Angels Arcusa; José Ignacio Chacón; Pedro Sánchez-Rovira; Arrate Plazaola; Montserrat Muñoz; Laia Paré; Joel S Parker; Nuria Ribelles; Begoña Jimenez; Abdul Aziz Bin Aiderus; Rosalía Caballero; Barbara Adamo; Mitch Dowsett; Eva Carrasco; Miguel Martín; J Michael Dixon; Charles M Perou; Emilio Alba Journal: Clin Cancer Res Date: 2016-11-30 Impact factor: 12.531
Authors: Vince Kornél Grolmusz; Katalin Karászi; Tamás Micsik; Eszter Angéla Tóth; Katalin Mészáros; Gellért Karvaly; Gábor Barna; Péter Márton Szabó; Kornélia Baghy; János Matkó; Ilona Kovalszky; Miklós Tóth; Károly Rácz; Péter Igaz; Attila Patócs Journal: Am J Cancer Res Date: 2016-09-01 Impact factor: 6.166
Authors: Norman Wolmark; Eleftherios P Mamounas; Frederick L Baehner; Steven M Butler; Gong Tang; Farid Jamshidian; Amy P Sing; Steven Shak; Soonmyung Paik Journal: J Clin Oncol Date: 2016-05-23 Impact factor: 44.544